|107.87||+0.1600||+0.15%||Vol 1.35M||1Y Perf -1.11%|
|Feb 2nd, 2023 13:16 DELAYED|
|0.75 0.70%||- -|
|Target Price||125.00||Analyst Rating||Strong Buy 1.33|
|Potential %||15.94||Finscreener Ranking||★★★ 48.41|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★ 39.51|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★+ 64.78|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||60.37||Earnings Rating||Sell|
|Market Cap||41.67B||Earnings Date||9th Feb 2023|
Today's Price Range
5 Year PE Ratio Range
|10 Years||2 677.82%|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||9th Feb 2023|
|Estimated EPS Next Report||0.26|
|EPS Growth Next 5 Years %||32.90|
|Avg. Weekly Volume||2.04M|
|Avg. Monthly Volume||2.50M|
|Avg. Quarterly Volume||2.48M|
DexCom Inc. (NASDAQ: DXCM) stock closed at 107.71 per share at the end of the most recent trading day (a 0.58% change compared to the prior day closing price) with a volume of 2.85M shares and market capitalization of 41.67B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 7000 people. DexCom Inc. CEO is Kevin R. Sayer.
The one-year performance of DexCom Inc. stock is -1.11%, while year-to-date (YTD) performance is -4.88%. DXCM stock has a five-year performance of 652.16%. Its 52-week range is between 66.8925 and 134.765, which gives DXCM stock a 52-week price range ratio of 60.37%
DexCom Inc. currently has a PE ratio of 263.20, a price-to-book (PB) ratio of 24.52, a price-to-sale (PS) ratio of 20.30, a price to cashflow ratio of 72.20, a PEG ratio of 2.32, a ROA of 4.07%, a ROC of 6.08% and a ROE of 10.01%. The company’s profit margin is 11.91%, its EBITDA margin is 15.50%, and its revenue ttm is $2.09 Billion , which makes it $5.42 revenue per share.
Of the last four earnings reports from DexCom Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.26 for the next earnings report. DexCom Inc.’s next earnings report date is 09th Feb 2023.
The consensus rating of Wall Street analysts for DexCom Inc. is Strong Buy (1.33), with a target price of $125, which is +15.94% compared to the current price. The earnings rating for DexCom Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
DexCom Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
DexCom Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.42, ATR14 : 3.57, CCI20 : -36.51, Chaikin Money Flow : 0.06, MACD : -1.62, Money Flow Index : 54.84, ROC : -0.70, RSI : 47.41, STOCH (14,3) : 67.14, STOCH RSI : 1.00, UO : 63.77, Williams %R : -32.86), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of DexCom Inc. in the last 12-months were: Barbara E. Kahn (Sold 2 766 shares of value $1 219 757 ), Barry J. Regan (Sold 2 212 shares of value $1 106 000 ), Chad Patterson (Sold 3 973 shares of value $1 701 249 ), Jereme M. Sylvain (Sold 3 000 shares of value $451 230 ), Kevin R. Sayer (Sold 55 607 shares of value $8 974 833 ), Matthew Vincent Dolan (Sold 4 377 shares of value $1 857 125 ), Paul R. Flynn (Sold 8 988 shares of value $1 110 018 ), Shelly Ramasamy Selvaraj (Sold 2 366 shares of value $949 405 ), Steven R. Pacelli (Sold 5 574 shares of value $1 051 855 )
Fri, 28 Oct 2022 01:55 GMT Dexcom (DXCM) Receives a Buy from BTIG- TipRanks. All rights reserved.
Fri, 07 Oct 2022 16:35 GMT Dexcom (DXCM) Gets a Buy from Stifel Nicolaus- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.